It is possible that FAP could be a reliable biomarker for the diagnosis and prognosis of ccRCC because of its role in the ccRCC progression via triggering the PI3K/AKT/mTOR signaling pathway. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.